Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

To evaluate the clinical efficacy of perioperative treatment with S-1 + oxaliplatin (SOX)+ HLX10 compared with SOX as the control in patients with cT3-4N1-3M0 PD-L1-positive (CPS ≥ 5) locally advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, in a placebo-controlled, double-blind, randomized phase II investigator-initiated clinical study.

Trial Details

NCT ID
NCT07699939
Phase
PHASE2
Sponsor
National Cancer Center, Japan
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • serplulimab
  • Placebo
Locations (sample)
  • Chiba, Chiba, Japan|35.6,140.11667
  • Fukuoka, Fukuoka, Japan|33.6,130.41667
  • Gifu, Gifu, Japan|35.42291,136.76039
  • Maebashi, Gunma, Japan|36.4,139.08333
  • Hiroshima, Hiroshima, Japan|34.4,132.45

Key Eligibility Criteria

  • 1\) Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma at the study site. (For gastroesophageal junction a…
  • 2\) Tumor tissue determined to be PD-L1 positive (CPS \>= 5) based on pre-screening evaluation by the central laboratory.
  • 3\) Diagnosis of cT3-4N1-3M0 disease according to the AJCC/UICC-TNM 8th edition based on assessments performed within 28 days prior to randomizatio…
  • 4\) Judged by the investigator as capable of undergoing R0 resection.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →